Redeye comments on Immunicum’s Q3 2021 report, which came without any surprises. Looking forward, we anticipate important clinical trial data from the company’s ADVANCE II and ILIAD phase Ib trials during the fourth quarter. Further, the company plans to announce its updated clinical development strategy during Q1 2022.
LÄS MER